MRC Technology has completed the move of its Centre for Therapeutics Discovery to state-of-the-art laboratory facilities at the SBC campus. Some teams will also relocate from the central London office. The charity will still have an office in London, along with laboratories and an office in Edinburgh.
MRC Technology, an independent life science medical research charity, has appointed Dr Les Hughes and Dr Mike Romanos to the board of trustees, with effect from 1 March 2016.
MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences collaborate on antibody drug development
MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences (IPS-CAS) have signed a collaboration agreement to develop new therapeutic antibodies from research originating in China.
Dementia Consortium welcomes MSD as a new partner in their global venture to accelerate drug discovery for neurodegenerative disease. MSD is the latest pharmaceutical company to join the Dementia Consortium – a £4.5 million charity-industry partnership between Alzheimer’s Research UK, MRC Technology and pharmaceutical companies Abbvie, Astex, Eisai and Lilly.
New dementia drug discovery efforts get underway this month at the University of South Florida, thanks to £875,000 funding from the Dementia Consortium. The US team of academics will work with drug development experts at UK-based MRC Technology, to target the immune system in a bid to halt nerve cell damage.
The Dementia Consortium has welcomed AbbVie as new pharmaceutical partner, joining medical research charity MRC Technology, Alzheimer’s Research UK, the UK’s leading dementia research charity, and pharmaceutical companies Astex, Eisai and Lilly.
Partnership between MRC Technology and Alzheimer's Association will focus on finding new ways to translate fundamental research findings into new medicines that manage and treat Alzheimer’s disease.